Gudang Garam Stock Continues to Decline in Indonesia's Anti-Smoking Campaign

Dec.08.2022
Gudang Garam Stock Continues to Decline in Indonesia's Anti-Smoking Campaign
Susilo Wonowidjojo's wealth declined due to falling stocks of his family's cigarette company, Gudang Garam, amid anti-smoking campaigns.

Susilo Wonowidjojo's wealth has further declined this year as the stock of his family's cigarette manufacturer Gudang Garam continues its three-year slump amid the Indonesian government's anti-smoking campaign. His net worth dropped by 27% to $3.5 billion, placing him at 14th on Indonesia's richest 50 list, down seven spots from last year.


Despite a slight improvement in sales during the first nine months of 2022, net profit has decreased by 64% year-on-year to 15 trillion Indonesian rupiahs (96 million US dollars), primarily due to the government's increase in tobacco consumption tax in January (following a 27% drop in revenue in 2021). Taxes make up over 85% of the company's total sales costs, resulting in a profit margin of 1.6%, down from 4.4% last year. Additionally, in November, Finance Minister Sri Mulyani Indrawati announced additional tax increases in 2023 and 2024. The company has stated its plans to raise prices.


In recent years, Indonesia has strengthened its measures to combat smoking, especially among young people. Approximately one quarter of the country's 276 million population smoke cigarettes. Overseas sales for Gudang Garam have also declined, dropping nearly 15% year-on-year in 2021 to 1.8 billion cigarettes. The company diversified its operations in 2019 with the construction of toll roads and is currently building the Dhoho airport in Kediri, East Java at a cost of 600 million dollars, which is expected to open in October of next year.


Gudang Garam was founded in 1958 by Susilo's father, Surya Wonowidjojo. Since 2009, Susilo has served as the CEO of the Kediri-based company, with his sister Juni Setiawati serving as the executive commissioner. In June, Susilo's son Indra was appointed as the Vice President Director.


2FIRSTS will continue to report on this issue, with further updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Fontem Sues FDA Over Refusal-to-File Decision for Nicotine Pouch PMTAs
Fontem Sues FDA Over Refusal-to-File Decision for Nicotine Pouch PMTAs
According to a complaint filed on March 17 in the U.S. District Court for the Northern District of Texas, Fontem US, LLC and Texas retailer OM Investment, LLC sued the Food and Drug Administration and the Department of Health and Human Services over FDA’s refusal-to-file decision for certain Zone nicotine pouch PMTAs.
Mar.19 by 2FIRSTS.ai
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Group announced that net sales for October–December 2025 rose 15% year-on-year to SEK 1,052.2 million, or 19% in constant currency terms. The company recorded 28% volume growth in the nicotine pouch category during the quarter. The number of orders increased to 1.34 million, and active consumers rose to 630,000, marking the highest level in the company’s history. CEO Gavin O’Dowd said the company’s accelerating topline performance in the US and UK positions it for a strong 2026.
Market
Feb.22
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
Korea Disease Control and Prevention Agency’s Youth Health Panel Survey (2025) Final Results Report says key adolescent health indicators worsen as students move up grade levels. By 11th grade, lifetime tobacco experience rose to 9.59%. Among 11th-grade girls, current use of liquid e-cigarettes (1.54%) surpassed conventional cigarettes (1.33%) for the first time.
Feb.10 by 2FIRSTS.ai
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA announced it will convene a Feb. 10, 2026 roundtable with small tobacco product manufacturers to gather feedback on PMTA submissions for ENDS products. The discussion will be viewable online, and a public docket is open for comments through March 12, 2026.
Feb.10 by 2FIRSTS.ai
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03